Letters sent to healthcare professionals in March 2016

In March 2016, letters were sent regarding SGLT2 inhibitors, insulin lispro, natalizumab, noradrenaline, radium-223 dichloride, aflibercept and idelalisib.

From:
Medicines and Healthcare products Regulatory Agency
Published
18 April 2016
Therapeutic area:
Cancer, Dentistry, Dermatology, Endocrinology, diabetology and metabolism, Infectious disease, Neurology and Radiology and imaging

In March 2016, letters were sent to healthcare professionals regarding:

  • .SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis during treatment (see also the article in this issue)
  • insulin lispro (Humalog 200 units/mL KwikPen): correct use to minimise medication errors
  • natalizumab (Tysabri▼): updates to PML risk minimisation measures (see also the article in this issue)
  • noradrenaline (norepinephrine) 0.08 mg/mL (4 mg in 50 mL) solution for infusion in a vial: potential risk of medication errors
  • radium-223 dichloride (Xofigo▼): change in NIST standard reference material – information on implementation
  • aflibercept (Zaltrap▼): information on the risk of osteonecrosis of the jaw (see also the article in this issue)
  • idelalisib (Zydelig▼): restrictions in use for the treatment of chronic lymphocytic leukaemia and relapsed follicular lymphoma following new clinical trial results

Article citation: Drug Safety Update volume 9 issue 9, April 2016: 10.

Updates to this page

Published 18 April 2016